Vaccinex(VCNX)

Focus: Vaccinex is a public biotech company focused on human therapeutic monoclonal antibodies and targeted biological therapies, primarily in oncology, neurology, and immunology. The company operates at pre-revenue scale with minimal commercial revenue and a heavily research-focused business model.

Vaccines

Profile data last refreshed 14h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Vaccinex

AI assessmentNot Hiring

No open roles listed right now. Follow Vaccinex to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$570K

Pipeline & Clinical Trials

Anti-SEMA4D Monoclonal Antibody VX15/2503

Colon Carcinoma Metastatic in the Liver

PHASE_1

Clinical Trials (1)

NCT03373188VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Phase 1

Help build intelligence for Vaccinex

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a diverse pipeline of 12 clinical programs across high-impact areas including oncology (melanoma, NSCLC, pancreatic cancer), neurology (Huntington's disease, Alzheimer's), and immunology with multiple combination strategies.
Work on validated target (SEMA4D) with multiple clinical indications and modalities, offering exposure to both monoclonal antibody development and dendritic cell therapies.
Early-stage opportunity with public company resources; the 2908% R&D intensity reflects deep commitment to pipeline advancement over near-term commercialization.

Watch Out For

Severe cash constraint: $2M cash position against $17M annual R&D spend (FY 2024) with cumulative losses exceeding $40M, creating imminent funding crisis risk and potential restructuring.
No marketed products and zero Phase 3 programs; 8 of 9 trials are Phase 1, indicating 5+ years minimum to meaningful value inflection with very high attrition probability.
Effectively no hiring signal (0 active job postings) and minimal headcount data suggest the company is in capital preservation mode, not expansion.

Generated by Claude from Vaccinex's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Anti-SEMA4D Monoclonal Antibody VX15/2503

Metastatic Melanoma

PHASE_1

Dendritic Cell

HER2-positive Breast Cancer

PHASE_1

Clinical Trials (1)

NCT05378464Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Phase 1

VX15/2503

Multiple Sclerosis

PHASE_1

Clinical Trials (1)

NCT01764737Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Phase 1

VX15/2503

Squamous Cell Carcinoma of the Head and Neck

PHASE_1

Clinical Trials (1)

NCT03690986VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Phase 1

VX15/2503

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT01313065Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors

Phase 1

Pepinemab

Alzheimer Disease

PHASE_1_2

Clinical Trials (1)

NCT04381468SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Phase 1/2

Avelumab and Pepinemab

Metastatic Pancreatic Adenocarcinoma

PHASE_1_2

Clinical Trials (1)

NCT05102721Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

Phase 1/2

VX15/2503 + avelumab

Carcinoma, Non-Small-Cell Lung

PHASE_1_2

Clinical Trials (1)

NCT03268057VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer

Phase 1/2

VX15/2503

Huntington's Disease

PHASE_2

Clinical Trials (1)

NCT02481674A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 9 clinical trials

Top TAs: Oncology, Neurology

Publications: 25 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

6 pipeline

Neurology

3 pipeline

Marketed

Pipeline

Financials (FY2024)

Revenue

$570K107%

R&D Spend

$17M(2908%)19%

Net Income

-$20M

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer.

Cancer cell

2026

PMID:41895277

Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier.

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Vaccinex(VCNX)

About Vaccinex

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Vaccinex(3)

Open Jobs (0)

Financials (FY2024)

Research Publications(10)